Relationship of international normalized ratio to bleeding and thromboembolism rates in Taiwanese patients receiving vitamin K antagonist after mechanical valve replacement

Journal of the Formosan Medical Association

Volumn 104, Issue 4, 2005, Pages 236-243

  Yu, Hsi Yu ^a,b   Liu, Chih Ho ^b,c   Chen, Yih Sharng ^a   Wang, Shoei Shen ^a   Chu, Shu Hsun ^a,d   Lin, Fang Yue ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CATHAY GENERAL HOSPITAL   (Taiwan)

^d FAR EASTERN MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Anticoagulants; Follow up studies; Heart valve prosthesis; International normalized ratio; Taiwan

Indexed keywords

ANTIVITAMIN K; WARFARIN; ANTICOAGULANT AGENT; VITAMIN K GROUP;

ADULT; AGED; AORTA VALVE REPLACEMENT; ARTICLE; BLEEDING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REPLACEMENT; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; TAIWAN; THROMBOEMBOLISM; ASIAN; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; ETHNOLOGY; HEART VALVE REPLACEMENT; MIDDLE AGED;

ANTICOAGULANTS; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; HEART VALVE PROSTHESIS IMPLANTATION; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; MIDDLE AGED; THROMBOEMBOLISM; VITAMIN K; WARFARIN;

EID: 33746712280     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Vink R, Kraaijenhagen RA, Hutten BA, et al: The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. J Am Coll Cardiol 2003;42:2042-8.
2. Edmunds LH Jr, Clark RE, Cohn LH, et al: Guidelines for reporting morbidity and mortality after cardiac valvular operations. Ad Hoc Liaison Committee for Standardizing Definitions of Prosthetic Heart Valve Morbidity of The American Association for Thoracic Surgery and The Society of Thoracic Surgeons. J Thorac Cardiovasc Surg 1996;112:708-11.
3. Butchart EG, Payne N, Li HH, et al: Better anticoagulation control improves survival after valve replacement. J Thorac Cardiovasc Surg 2002;123:715-23.
4. Van Nooten GJ, Van Belleghem Y, Caes F, et al: Lower-intensity anticoagulation for mechanical heart valves: a new concept with the ATS bileaflet aortic valve. J Heart Valve Dis 2003;12:495-501.
5. Cannegieter SC, Rosendaal FR, Wintzen AR, et al: Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995;333:11-7.
6. Horstkotte D, Schulte HD, Bircks W, et al: Lower intensity anticoagulation therapy results in lower complication rates with the St. Jude Medical prosthesis. J Thorac Cardiovasc Surg 1994;107:1136-45.
7. Stein PD, Alpert JS, Bussey HI, et al: Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119:220S-7S.
8. Saour JN, Sieck JO, Mamo LA, et al: Trial of different intensities of anticoagulation in patients with prosthetic heart valves. N Engl J Med 1990;322:428-32.
9. Matsuyama K, Matsumoto M, Sugita T, et al: Anticoagulant therapy in Japanese patients with mechanical mitral valves. Circ J 2002;66:668-70.
10. Nakano K, Koyanagi H, Hashimoto A, et al: Twelve years' experience with the St. Jude Medical valve prosthesis. Ann Thorac Surg 1994;57:697-702.
11. Chenhsu RY, Chiang SC, Chou MH, et al: Long-term treatment with warfarin in Chinese population. Ann Pharmacother 2000;34:1395-401.
12. Chan LY, Yuen PM, Lo WK, et al: Symptomatic venous thromboembolism in Chinese patients after gynecologic surgery: incidence and disease pattern. Acta Obstet Gynecol Scand 2002;81:343-6.
13. Mok CK, Hoaglund FT, Rogoff SM, et al: The incidence of deep vein thrombosis in Hong Kong Chinese after hip surgery for fracture of the proximal femur. Br J Surg 1979;66:640-2.
14. Nandi P, Wong KP, Wei WI, et al: Incidence of postoperative deep vein thrombosis in Hong Kong Chinese. Br J Surg 1980;67:251-3.
15. Chan CW, Hoaglund FT: Pulmonary thromboembolism and venous thrombosis in the Chinese. Clin Orthop Relat Res 1980;150:253-60.
16. Yu HY, Ho YL, Chu SH, et al: Long-term evaluation of Carpentier-Edwards porcine bioprosthesis for rheumatic heart disease. J Thorac Cardiovasc Surg 2003;126:80-9.
17. van Doom CA, Stoodley KD, Saunders NR, et al: Mitral valve replacement with the Carpentier-Edwards standard bioprosthesis: performance into the second decade. Eur J Cardiothorac Surg 1995;9:253-8.
18. Fann JI, Miller DC, Moore KA, et al: Twenty-year clinical experience with porcine bioprostheses. Ann Thorac Surg 1996;62:1301-11.
19. Akins CW, Carroll DL, Buckley MJ, et al: Late results with Carpentier-Edwards porcine bioprosthesis. Circulation 1990;82: IV65-IV74.
20. Grunkemeier GL, Li HH, Naftel DC, etal: Long-term performance of heart valve prostheses. Curr Probl Cardiol 2000;25:73-154.
21. Zellner JL, Kratz JM, Crumbley AJ, et al: Long-term experience with the St. Jude Medical valve prosthesis. Ann Thorac Surg 1999;68:1210-8.
22. Bonow RO, Carabello B, de LA Jr, et al: Guidelines for the management of patients with valvular heart disease: executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Valvular Heart Disease). Circulation 1998;98:1949-84.
23. Rettie AE, Tai G, Veenstra DL, et al: CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians. Blood 2003;101:2896-7.
24. Takahashi H, Wilkinson GR, Caraco Y, et al: Population differences in S-warfarin metabolism between CYP2C9 genotype-matched Caucasian and Japanese patients. Clin Pharmacol Ther 2003;73:253-63.
25. Leung AY, Chow HC, Kwong YL, et al: Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 2001;98:2584-7.
26. Ko WJ, Chu SH: A new dosing regimen for esmolol to treat supraventricular tachyarrhythmia in Chinese patients. J Am Coll Cardiol 1994;23:302-6.
27. Fugh-Berman A: Herb-drug interactions. Lancet 2000;355:134-8.